# US Hepatitis C Diagnosis Treatment Market > US Hepatitis C Diagnosis and Treatment Market Research Report By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests, others), By Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation, others) and By End User (Hospitals & Clinics, Diagnostic Centers, others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.07% - **2024:** $ 10 Billion - **2025:** $ 10.91 Billion - **2035:** $ 26 Billion - **Key Players:** AbbVie (US), Gilead Sciences (US), Merck & Co (US), Bristol-Myers Squibb (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), GlaxoSmithKline (GB), Hoffmann-La Roche (CH) **Report ID:** MRFR/MED/15149-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-hepatitis-c-diagnosis-treatment-market-16677 --- ## Market Summary ## **US Hepatitis C Diagnosis and Treatment Market Overview** As per MRFR analysis, the US Hepatitis C Diagnosis and Treatment Market Size was estimated at 9.28 (USD Billion) in 2023. The US Hepatitis C Diagnosis and Treatment Market Industry is expected to grow from 10.2 (USD Billion) in 2024 to 26.2 (USD Billion) by 2035. The US Hepatitis C Diagnosis and Treatment Market CAGR (growth rate) is expected to be around 8.955% during the forecast period (2025 - 2035). ### **Key US Hepatitis C Diagnosis and Treatment Market Trends Highlighted** The US Hepatitis C Diagnosis and Treatment Market is experiencing significant transformation driven by advancements in technology, shifts in healthcare policies, and increasing awareness of the disease. Key market drivers include the implementation of the Affordable Care Act, which has expanded access to healthcare services, allowing more individuals to undergo testing and treatment for Hepatitis C. Moreover, increased screening recommendations by the Centers for Disease Control and Prevention (CDC) have encouraged healthcare providers to diagnose patients earlier, contributing to better treatment outcomes. The opportunities to be explored in this market revolve around innovative treatment options, particularly direct-acting antivirals (DAAs) that have shown to be highly effective in curing Hepatitis C. The rise of telemedicine presents a unique opportunity to reach patients in remote areas, ensuring that they receive timely diagnosis and treatment without geographical barriers. As policymakers and health organizations continue to focus on eliminating Hepatitis C as a public health threat, enhanced funding for education and outreach programs can further increase awareness and promote testing. Trends in recent times highlight a growing emphasis on patient-centered care, with healthcare systems adopting more holistic approaches to treatment. The integration of mental health services and substance use disorder treatment with Hepatitis C care signifies a shift towards comprehensive patient management. Furthermore, collaborations between pharmaceutical companies and public health entities are becoming more common, aiming to streamline the treatment process and enhance patient engagement. These evolving dynamics in the US Hepatitis C Diagnosis and Treatment Market are setting the stage for a future with improved outcomes and potential eradication of the disease. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Hepatitis C Diagnosis and Treatment Market Drivers** ### **Rising Prevalence of Hepatitis C** The US[Hepatitis C Diagnosis and Treatment Market](../../../reports/hepatitis-c-diagnosis-treatment-market-1569)Industry is experiencing significant growth due to the rising prevalence of Hepatitis C virus (HCV) infections. According to the Centers for Disease Control and Prevention (CDC), approximately 2.4 million people in the United States are currently living with chronic Hepatitis C, a number which has steadily increased over the past decade. This rise is attributed to factors such as the opioid crisis leading to increased intravenous drug use, a common transmission route for HCV. The National Institute on Drug Abuse (NIDA) has reported a 107% increase in opioid-related deaths during the last five years, reflecting a substantial increase in the population at risk for Hepatitis C. As the number of diagnosed cases rises, the demand for effective diagnostic and treatment options will continue to grow, thereby driving the US Hepatitis C Diagnosis and Treatment Market. ### **Advancements in Treatment Options** Innovations in the treatment landscape for Hepatitis C are significantly propelling the US Hepatitis C Diagnosis and Treatment Market Industry forward. Direct-acting antiviral agents (DAAs), which have revolutionized the treatment methodology, now boast cure rates exceeding 95% for many patients. The American Association for the Study of Liver Diseases (AASLD) reports that the development and approval of new DAAs have expanded treatment access and improved patient outcomes. As new formulations and combinations are continuously introduced, the efficacy of treatment is improving, encouraging patients to seek diagnosis and treatment. This results in a growth trajectory for the market, ensuring that healthcare providers are equipped with cutting-edge therapies to combat Hepatitis C effectively. ### **Government Initiatives and Funding** Government initiatives aimed at eradicating Hepatitis C are a critical driver in the US Hepatitis C Diagnosis and Treatment Market Industry. In 2020, the HCV Elimination Plan was launched under the auspices of the U.S. Department of Health and Human Services (HHS), which aims to reduce new Hepatitis C infections by 90% and eliminate Hepatitis C deaths by 65% by 2030. This plan includes increased funding for prevention, testing, and treatment programs. As part of the expansion, the HHS allocated significant grants to various states, enabling healthcare systems to improve their outreach and diagnosis capabilities. As such governmental support fosters a conducive environment for the adoption of new treatment methodologies, it inherently drives growth in the Hepatitis C market. ### **Increased Awareness and Screening Programs** The US Hepatitis C Diagnosis and Treatment Market Industry is being positively influenced by increased awareness about the disease and better screening programs. Campaigns spearheaded by organizations such as the CDC have resulted in increased screening among high-risk populations. Reports suggest that the number of Hepatitis C screening tests performed rose by nearly 60% between 2013 and 2021, reflecting successful awareness initiatives. With more individuals being screened, more people are being diagnosed and treated, leading to market growth. The Healthy People 2030 initiative emphasizes the importance of screening and early diagnosis, further propelling the need for enhanced diagnostic tools and treatment options in the US market. ## **US Hepatitis C Diagnosis and Treatment Market Segment Insights** ### **Hepatitis C Diagnosis and Treatment Market Diagnosis Insights** The United States Hepatitis C Diagnosis segment plays a pivotal role in the overarching framework of Hepatitis C Diagnosis and Treatment Market. This segment comprises various methods like Liver Function Tests, Liver Biopsy, Blood Tests, and other diagnostic approaches, all contributing significantly to the detection and management of Hepatitis C. Liver Function Tests serve as an essential tool in assessing the liver's health and function, allowing healthcare professionals to monitor the disease’s progression and evaluate the effectiveness of treatments. The Liver Biopsy, while less commonly performed due to the advent of non-invasive alternatives, remains a crucial diagnostic tool for determining the extent of liver damage and guiding the treatment course for patients who present with advanced liver disease. Blood Tests, particularly those that identify the presence of Hepatitis C antibodies and quantify the viral load, dominate this segment by providing vital information that aids in diagnosis and treatment planning. Beyond these prominent methods, there exists a variety of other diagnostic techniques and analyses that enhance the accuracy of diagnosing Hepatitis C and assessing liver health, which is increasingly important given the rising prevalence rates within the United States. The convergence of technological advancements and the ever-evolving landscape of clinical practices contributes to significant growth in this segment, as health professionals strive to implement quicker, more accurate diagnostic procedures. Moreover, ongoing education and awareness initiatives are vital to encourage early testing among at-risk populations, ultimately impacting the market positively. The rising prevalence of Hepatitis C, particularly among baby boomers and individuals with certain risk factors, necessitates an expanded range of diagnostic solutions, highlighting both opportunities and challenges within the US Hepatitis C Diagnosis and Treatment Market. As the healthcare landscape adapts to incorporate novel diagnostic tools and approaches, the segment continues to evolve, responding to the changing needs of patients and practitioners alike Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Hepatitis C Diagnosis and Treatment Market Treatment Insights** The Treatment segment of the US Hepatitis C Diagnosis and Treatment Market plays a critical role in managing and curing Hepatitis C, with a focus on various effective therapies. Antiviral medications are among the most prominent in this segment, significantly improving cure rates and minimizing the disease's long-term effects on liver health. Meanwhile, Immuno-Modulators are gaining traction for their potential to enhance the body’s immune response against the virus. Liver Transplantation remains a vital intervention for patients with advanced liver disease due to Hepatitis C, offering a chance at life for those facing severe complications. Additionally, the 'others' category includes emerging therapies and supportive treatments that address various aspects of patient care and overall health management. With patient populations increasing and treatment accessibility improving, the US Hepatitis C Diagnosis and Treatment Market is poised for ongoing growth driven by advancements in medical research and innovative treatment options. The rising awareness and screening efforts by health organizations further contribute to the demand within this segment, highlighting the critical importance of effective treatment solutions in combating Hepatitis C in the United States. ### **Hepatitis C Diagnosis and Treatment Market End User Insights** The End User segment of the US Hepatitis C Diagnosis and Treatment Market is crucial in shaping overall healthcare responses to this viral infection. Hospitals and clinics are often the primary touchpoints for patients seeking diagnosis and therapy, playing a pivotal role in managing patient care, especially given the increasing prevalence of Hepatitis C within certain demographics in the United States. Diagnostic centers serve as specialized facilities offering advanced testing methods, significantly enhancing the accuracy of diagnoses and thereby ensuring timely treatment initiation. Their importance cannot be understated as they frequently attract patients requiring rapid and comprehensive screenings. Additionally, other healthcare providers contribute to the delivery of care by supporting follow-up treatments and referrals, thereby creating a well-rounded healthcare ecosystem. With rising awareness regarding Hepatitis C and advancements in treatment options, the demand for services across all End User categories is likely to see sustained growth. This growth is propelled by ongoing public health initiatives aimed at increasing testing, reducing stigma, and enhancing patient education, thus ensuring that more individuals receive the necessary care and support. This dynamic within the End User landscape underscores the importance of collaboration among healthcare entities to effectively combat Hepatitis C in the United States. ## **US Hepatitis C Diagnosis and Treatment Market Key Players and Competitive Insights** The US Hepatitis C Diagnosis and Treatment Market is a dynamic and rapidly evolving landscape characterized by significant competition among various key players. This market is driven by the increasing prevalence of hepatitis C virus infections, advancements in diagnostic technologies, and the development of innovative treatment solutions, which together create a robust environment for both established companies and new entrants. Competitive insights within this market illustrate how companies leverage their research capabilities, marketing strategies, and collaboration with healthcare providers to enhance their therapeutic offerings and capture market share. The presence of effective antiviral therapies that offer high cure rates has intensified the competitive nature of this sector as firms strive to differentiate themselves through novel products, pricing strategies, patient access initiatives, and educational outreach. Merck and Co plays a significant role in the US Hepatitis C Diagnosis and Treatment Market with a strong emphasis on research and development, focusing on creating effective drugs to combat hepatitis C. The company's robust presence is underpinned by its strong portfolio of antiviral therapies, which have shown promising results in treating the virus. Merck and Co boasts a powerful pipeline that continues to expand its reach within the market, supported by its substantial investment in clinical trials and collaborations with various organizations to enhance patient outcomes. The company's established reputation for quality and innovation allows it to maintain a competitive edge, particularly in navigating regulatory challenges and gaining market access for its therapeutic solutions. AstraZeneca holds a noteworthy position in the US Hepatitis C Diagnosis and Treatment Market by providing a portfolio of key antiviral medications designed to target hepatitis C. The firm has established a significant market presence through partnerships and strategic collaborations aimed at advancing treatment technologies. AstraZeneca's strength lies in its extensive research initiatives focusing on the nuances of hepatitis C viral strains, which has enabled the development of targeted treatments that demonstrate high efficacy. The company has also engaged in strategic mergers and acquisitions that bolster its capabilities in the hepatology space, leading to enhanced product offerings and expanded market penetration. By fostering innovation and focusing on patient-centric solutions, AstraZeneca solidifies its competitive advantage within this crucial healthcare segment in the US. ### **Key Companies in the US Hepatitis C Diagnosis and Treatment Market Include** ## **US Hepatitis C Diagnosis and Treatment Market Industry Developments** The US Hepatitis C Diagnosis and Treatment Market has recently seen notable developments, particularly with the ongoing advancements in direct-acting antiviral therapies, leading to improved treatment outcomes for patients. Companies such as Gilead Sciences and AbbVie continue to innovate with new treatment regimens that offer higher cure rates and reduced side effects. In September 2023, Merck and Co announced a collaboration with Novartis focusing on Research and Development for new antiviral agents aimed at Hepatitis C management. Concurrently, AstraZeneca and Bristol Myers Squibb are increasing their involvement in clinical trials to evaluate potential new therapies. Over the past two years, there has been a significant market valuation growth attributed to increased awareness and screening efforts supported by federal initiatives, such as the CDC's recommendations promoting testing among high-risk populations. Additionally, the market has also been affected by the economic pressures stemming from the COVID-19 pandemic, which altered healthcare access and treatment adherence for many Hepatitis C patients. These dynamics highlight the market's evolution as these companies strive to address the barriers in Hepatitis C diagnosis and treatment across diverse populations within the United States. ## **US Hepatitis C Diagnosis and Treatment Market Segmentation Insights** ### **Hepatitis C Diagnosis and Treatment Market Diagnosis Outlook** ### **Hepatitis C Diagnosis and Treatment Market Treatment Outlook** ### **Hepatitis C Diagnosis and Treatment Market End User Outlook** ## Market Drivers ### Expansion of Treatment Options The expansion of treatment options for hepatitis C is a crucial driver for the hepatitis c-diagnosis-treatment market. The introduction of new antiviral therapies, particularly direct-acting antivirals (DAAs), has revolutionized treatment protocols, offering higher cure rates and shorter treatment durations. As of now, these therapies are becoming increasingly accessible, with many insurance plans covering the costs. This accessibility is likely to encourage more patients to seek treatment, thereby increasing the overall market size. Furthermore, ongoing research and development efforts are expected to yield even more effective treatment options in the future, further propelling the hepatitis c-diagnosis-treatment market. ### Rising Prevalence of Hepatitis C The increasing prevalence of hepatitis C in the US is a critical driver for the hepatitis c-diagnosis-treatment market. As of recent estimates, approximately 2.4 million individuals are living with chronic hepatitis C in the US, highlighting a substantial patient population requiring diagnosis and treatment. This growing number necessitates enhanced screening and treatment options, thereby propelling market growth. The rising incidence is particularly notable among baby boomers, who are at a higher risk due to historical factors. Consequently, healthcare providers are focusing on improving diagnostic methods and treatment accessibility, which is likely to stimulate demand within the hepatitis c-diagnosis-treatment market. ### Government Initiatives and Funding Government initiatives aimed at combating hepatitis C are playing a pivotal role in shaping the hepatitis c-diagnosis-treatment market. Federal and state programs are increasingly allocating funds to enhance screening, treatment accessibility, and public awareness campaigns. For instance, the Centers for Disease Control and Prevention (CDC) has launched initiatives to promote hepatitis C testing among high-risk populations. Such efforts are likely to increase the number of diagnosed cases, subsequently boosting the demand for treatment options. The financial support from government entities is essential for developing new therapies and improving healthcare infrastructure, which could further stimulate market growth. ### Innovations in Diagnostic Technologies Technological advancements in diagnostic tools are significantly influencing the hepatitis c-diagnosis-treatment market. The introduction of highly sensitive and specific tests, such as polymerase chain reaction (PCR) and rapid diagnostic tests, has improved the accuracy of hepatitis C detection. These innovations facilitate early diagnosis, which is crucial for effective treatment outcomes. Moreover, the market is witnessing a shift towards point-of-care testing, allowing for immediate results and timely intervention. As healthcare systems increasingly adopt these advanced diagnostic technologies, the overall efficiency of hepatitis C management is expected to improve, thereby driving market growth. ### Growing Demand for Preventive Healthcare The rising emphasis on preventive healthcare is emerging as a significant driver for the hepatitis c-diagnosis-treatment market. As awareness of hepatitis C and its long-term health implications increases, more individuals are seeking preventive measures, including regular screenings. This trend is particularly evident among high-risk groups, such as individuals with a history of intravenous drug use or those who received blood transfusions before 1992. The proactive approach towards health management is likely to result in earlier diagnosis and treatment, thereby enhancing patient outcomes and driving market expansion. The hepatitis c-diagnosis-treatment market stands to benefit from this shift towards preventive healthcare. ## Future Outlook The [Hepatitis C Diagnosis Treatment Market](https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569) is projected to grow at a 9.07% CAGR from 2025 to 2035, driven by advancements in treatment options and increased screening initiatives. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in point-of-care diagnostic technologies - Expansion of patient assistance programs to enhance treatment access By 2035, the market is expected to achieve substantial growth, driven by innovative solutions and improved patient access. ## Segment Insights ### By Diagnosis: Blood Tests (Largest) vs. Liver Biopsy (Fastest-Growing) In the US hepatitis c-diagnosis-treatment market, blood tests hold the largest share, primarily due to their non-invasive nature and widespread applicability, making them the preferred choice among healthcare providers. In contrast, liver biopsies, while less common due to their invasive nature, are gaining traction as the fastest-growing segment due to advancements in diagnostic techniques that enhance their safety and reliability. The market is witnessing a trend towards more efficient and accurate diagnostic methods, with increasing adoption of innovative technologies driving growth. Factors such as rising incidences of hepatitis C, heightened awareness about the disease, and improved healthcare access are accelerating the demand for these diagnostic solutions. As healthcare providers seek to enhance patient outcomes, the focus on accurate liver function tests is likely to intensify, further shaping the dynamics of the market. Blood Tests (Dominant) vs. Liver Biopsy (Emerging) Blood tests are the dominant segment in the hepatitis c-diagnosis-treatment market, valued for their ease of use and ability to provide rapid results, which facilitate timely treatment decisions. Their non-invasive nature makes them a preferred diagnostic tool among both physicians and patients. In contrast, liver biopsies, although traditionally seen as invasive, are emerging as a valuable option in the market. With advancements in imaging technology and techniques, they are becoming more accurate and safer, thus appealing to specialists who seek deeper insights into liver conditions. The growth of this segment is supported by the increasing need for precise diagnosis in complex cases, signaling a shift towards more comprehensive diagnostic approaches. ### By Treatment: Antiviral Medications (Largest) vs. Immune-Modulators (Fastest-Growing) In the US hepatitis c-diagnosis-treatment market, Antiviral Medications represent the largest segment, dominating market share with a significant lead over other treatment options. Following closely, Immune-Modulators have begun to capture increasing attention from both healthcare professionals and patients, reflecting changing treatment paradigms that emphasize immune response mechanisms. The growth trends for this segment are heavily influenced by ongoing clinical advancements in antiviral therapies that enhance viral clearance rates. Moreover, the rising adoption of Immune-Modulators, fueled by their potential for improving patient outcomes, positions them as the fastest-growing treatment option. The market is also shaped by trends emphasizing personalized medicine and the exploration of combination therapies that leverage the benefits of multiple treatment modalities. Antiviral Medications (Dominant) vs. Immune-Modulators (Emerging) Antiviral Medications remain the dominant force in the market, recognized for their efficacy in achieving sustained virologic response (SVR) among chronic hepatitis C patients. These treatments, which include novel direct-acting antivirals (DAAs), are preferred due to their high cure rates and minimal side effects. In contrast, Immune-Modulators are emerging as a vital complement, enhancing the body’s immune defense against the virus and demonstrating promising results in clinical trials. The growing interest in Immune-Modulators is driven by their unique ability to address the viral lifecycle and support liver function, representing a shift toward integrated treatment approaches that may improve long-term success rates in managing hepatitis C. ### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) In the US hepatitis c-diagnosis-treatment market, Hospitals & Clinics hold the largest share, driven by their extensive capabilities in providing comprehensive healthcare services and advanced treatment options. Diagnostic Centers, while smaller in market share, are seeing rapid growth as they become pivotal in early detection and personalized treatment strategies for patients with hepatitis C. These centers are increasingly becoming specialized facilities that cater to the rising demand for rapid and accurate diagnostic services. The growth trends in this segment are influenced by several factors, including the increasing prevalence of hepatitis C and the ongoing advancements in diagnostic technologies. Hospitals & Clinics benefit from established patient bases and integrated treatment protocols, while Diagnostic Centers are emerging as key players by offering targeted services that improve patient outcomes. This dynamic landscape is further enhanced by the growing emphasis on preventative care and the accessibility improvements in healthcare services across various demographics. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals & Clinics are the dominant players in the US hepatitis c-diagnosis-treatment market due to their comprehensive healthcare delivery capabilities, integrated treatment procedures, and established infrastructure. They provide not only diagnosis and treatment but also follow-up care, playing an essential role in managing chronic hepatitis C cases. On the other hand, Diagnostic Centers are emerging as critical entities that focus specifically on early detection and timely intervention, which are vital for effective hepatitis C management. They leverage advanced diagnostic technologies and specialized testing services, catering to a growing patient population, especially as awareness around hepatitis C increases. The synergy between these two segment values is vital, as it ensures patients receive complete care pathways from diagnosis to treatment. ## Competitive Benchmarking The hepatitis c-diagnosis-treatment market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of hepatitis C and the ongoing advancements in treatment options. Major players such as AbbVie (US), Gilead Sciences (US), and Merck & Co (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. AbbVie (US) focuses on innovation through the development of new therapies, while Gilead Sciences (US) emphasizes strategic partnerships to expand its treatment portfolio. Merck & Co (US) is actively pursuing mergers and acquisitions to bolster its research capabilities, thereby shaping a competitive environment that is increasingly reliant on innovation and collaboration.The market structure appears moderately fragmented, with several key players exerting influence over various segments. Companies are employing tactics such as localizing manufacturing and optimizing supply chains to enhance operational efficiency. This collective approach not only strengthens their market presence but also fosters a competitive atmosphere where agility and responsiveness to market demands are paramount. In October AbbVie (US) announced a collaboration with a leading biotech firm to accelerate the development of a novel hepatitis C treatment. This strategic move is likely to enhance AbbVie's research capabilities and expand its therapeutic offerings, positioning the company favorably in a market that increasingly values innovative solutions. The partnership underscores the importance of collaboration in driving advancements in treatment options. In September Gilead Sciences (US) launched a new digital platform aimed at improving patient engagement and adherence to hepatitis C therapies. This initiative reflects a growing trend towards digital transformation in healthcare, suggesting that Gilead is keen on leveraging technology to enhance patient outcomes. By integrating digital tools into its treatment protocols, Gilead may strengthen its competitive edge in a market that is becoming more patient-centric. In August Merck & Co (US) completed the acquisition of a smaller pharmaceutical company specializing in hepatitis C diagnostics. This acquisition is indicative of Merck's strategy to enhance its diagnostic capabilities, which could lead to improved patient identification and treatment initiation. Such strategic actions highlight the importance of a comprehensive approach to hepatitis C management, encompassing both treatment and diagnosis. As of November current trends in the hepatitis c-diagnosis-treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift may ultimately redefine the landscape, emphasizing the need for companies to adapt and innovate in order to maintain their competitive positions. ## Recent News & Developments The US Hepatitis C Diagnosis and Treatment Market has recently seen notable developments, particularly with the ongoing advancements in direct-acting antiviral therapies, leading to improved treatment outcomes for patients. Companies such as Gilead Sciences and AbbVie continue to innovate with new treatment regimens that offer higher cure rates and reduced side effects. In September 2023, Merck and Co announced a collaboration with Novartis focusing on Research and Development for new antiviral agents aimed at Hepatitis C management. Concurrently, AstraZeneca and Bristol Myers Squibb are increasing their involvement in clinical trials to evaluate potential new therapies. Over the past two years, there has been a significant market valuation growth attributed to increased awareness and screening efforts supported by federal initiatives, such as the CDC's recommendations promoting testing among high-risk populations. Additionally, the market has also been affected by the economic pressures stemming from the COVID-19 pandemic, which altered healthcare access and treatment adherence for many Hepatitis C patients. These dynamics highlight the market's evolution as these companies strive to address the barriers in Hepatitis C diagnosis and treatment across diverse populations within the United States. ## Report Scope | MARKET SIZE 2024 | 10.0(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 10.91(USD Billion) | | MARKET SIZE 2035 | 26.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.07% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Gilead Sciences (US), Merck & Co (US), Bristol-Myers Squibb (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), GlaxoSmithKline (GB), Hoffmann-La Roche (CH) | | Segments Covered | Diagnosis, Treatment, End User | | Key Market Opportunities | Advancements in point-of-care testing enhance early diagnosis in the hepatitis c-diagnosis-treatment market. | | Key Market Dynamics | Regulatory changes and technological advancements drive innovation in hepatitis C diagnosis and treatment options. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US hepatitis c-diagnosis-treatment market in 2024?** A: The overall market valuation was $10.0 Billion in 2024. **Q: What is the projected market valuation for the US hepatitis c-diagnosis-treatment market by 2035?** A: The projected market valuation for 2035 is $26.0 Billion. **Q: What is the expected CAGR for the US hepatitis c-diagnosis-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 9.07%. **Q: Which companies are considered key players in the US hepatitis c-diagnosis-treatment market?** A: Key players include AbbVie, Gilead Sciences, Merck & Co, Bristol-Myers Squibb, Roche, Johnson & Johnson, Novartis, GlaxoSmithKline, and Hoffmann-La Roche. **Q: What were the valuations for liver function tests in the diagnosis segment in 2024?** A: The valuation for liver function tests in the diagnosis segment was $2.0 Billion in 2024, projected to reach $5.0 Billion. **Q: How much did blood tests contribute to the diagnosis segment in 2024?** A: Blood tests contributed $4.0 Billion to the diagnosis segment in 2024, with a projection of $10.0 Billion. **Q: What is the projected valuation for antiviral medications in the treatment segment by 2035?** A: The projected valuation for antiviral medications in the treatment segment is $10.0 Billion by 2035. **Q: What were the valuations for liver transplantation in the treatment segment in 2024?** A: The valuation for liver transplantation in the treatment segment was $2.0 Billion in 2024, expected to reach $6.0 Billion. **Q: What is the projected market size for hospitals and clinics as end users by 2035?** A: The projected market size for hospitals and clinics as end users is $10.0 Billion by 2035. **Q: What were the valuations for diagnostic centers in the end user segment in 2024?** A: The valuation for diagnostic centers in the end user segment was $3.0 Billion in 2024, projected to reach $8.0 Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hepatitis-c-diagnosis-treatment-market-16677*